Abstract Berdasarkan data Riset Kesehatan Dasar (Riskesdas) 2018, prevalensi penyakit
jantung koroner sebagai etiologi utama sindrom koroner akut (SKA) di Indonesia sebesar 1 …

Background The safety and efficacy of dual antiplatelet therapy (DAPT) in medically treated
acute myocardial infarction (AMI) patients with baseline thrombocytopenia (platelet count< …

Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor antagonist is a
fundamental component of acute coronary syndrome (ACS) management, with longstanding …

Aims We aim to research the efficacy and safety of single (SAPT), dual (DAPT), and triple
(TAPT) antiplatelets approaches across IHD patients undergoing PCI. Methods and results A …

Dual antiplatelet therapy is a key element in the pharmacological treatment of coronary heart
disease. It consists in the combination of aspirin (ASA) and a P2Y12 platelet inhibitor. This …

Objective: To investigate the impact of different regimens of dual antiplatelet therapy (DAPT)
on the prognosis of acute coronary syndrome (ACS) patients with high risk of both ischemia …

Long-term dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (clopidogrel,
prasugrel, or ticagrelor) is recommended after acute coronary syndrome (ACS) to reduce the …

Background: Long-term use of dual antiplatelet therapy increases the risk of bleeding but
reduces the risk of major adverse cardiac events. This systematic review will discuss the …

Background: Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent
P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) …

Background Randomized controlled trials have shown a reduced risk of ischemic events
and an increased risk of bleeding in patients treated with prolonged dual anti-platelet …